Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: Association of decreased plasminogen activator inhibitor 2 with lymph node metastasis

British Journal of Cancer

Volumn 78, Issue 6, 1998, Pages 833-839

  Yoshino, H ^a   Endo, Y ^a   Watanabe, Y ^a   Sasaki, T ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Lung cancer; Lymph node metastasis; Plasminogen activator inhibitor 2; Prognosis

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 2; UROKINASE;

ARTICLE; CANCER INVASION; EXTRACELLULAR MATRIX; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0031679213     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.588     Document Type: Article

References (38)

1. Anthony ED, Shen Y, Ruegg M and Medcalf RL (1996) Molecular mechanisms governing tumour-necrosis-factor-mediated regulation of plasminogen activator inhibitor type-2 gene expression. Eur J Biochem 241: 93-100
2. Baker MS, Bleakley P, Woodrow GC and Doe F (1990) Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PA1-2 and subsequent effects on extracellular matrix degradation. Cancer Res 50: 4676-4684
3. Blasi F, Stoppeli MP and Cubellis MV (1986) The receptor for urokinase-plasminogen activator. J Cell Biochem 32: 179-186
4. Bouchet C, Spyratos F, Martin PM, Hacene K, Gentile A and Oglobine J (1994) Prognostic value of plasminogen activator (uPA) and plaminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 69: 398-405
5. Cajot JF, Bamat J, Bergomelli GE, Kruithof EK, Medcalf RL, Testuz J and Sordat B (1990) Plasminogen-activator inhibitor type 1 is a potent inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. Proc Natl Acd Sci USA 87: 6936-6943
6. Carriero MV, Franco P, Del Vecchio S, Massa O, Botti G, D'Ainto G, Stoppelli MP and Salvatore M (1994) Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies. Cancer Res 54: 5445-5454
7. Cohen RL, Xi XP, Crewley CW, Lucas BK, Levinson AD and Schuman MA (1991) Effects of urokinase receptor occupancy on plasmin generation and proteolysis of basement membrane by human tumor cells. Blood 78: 479-487
8. Conboy JG, Chan J, Mohandas N and Kan YW (1988) Multiple protein 4.1 isoforms produced by alternative splicing in human erythroid cells. Proc Natl Acad Sci USA 85: 9062-9065
9. Cubellis MV, Wun TC and Blasi F (1990) Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 9: 1079-1085
10. Dano K, Andreason PA, Grondahl-Hansen J, Kristensen P, Nielsen LS and Skriver L (1985) Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44: 139-266
11. Del Vecchio S, Stoppelli MP, Carriero MV, Fonti R, Massa O, Li PY, Botti G, Cerra M, D'Aiuto G, Esposito G and Salvatore M (1993) Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels. Cancer Res 53: 3198-3206
12. Duggan C, Kennedy S, Kramer MD, Barnes C, Elvin P, McDermott E, O'Higgins N and Duffy MJ (1997) Plasminogen activator inhibitor type 2 in breast cancer. Br J Cancer 76: 622-627
13. Ellis V and Dano K (1991) Plasminogen activation by receptor-bound urokinase. Semin Thromb Hemost 17: 194-200
14. Foekens JA, Buessecker F, Peters HA, Krainnick U, Putten WLJ, Look MP, Klijn JGM and Kramer MD (1995) Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Rev 55: 1423-1427
15. Ganesh S, Sier CEM, Griffioen G, Vloedgraven HJM, de Boer A, Welvaart K, van de Velde CJH, van Krieken JHJM, Verheijen JH, Lamers CBHW and Verspaget HW (1994) Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 54: 4065-4071
16. Goldfarb RH, Murano G, Brundage R, Siegal GP, Terranova V. Garbisa S and Liotta LA (1986) Degradation of glycoprotein and collagenous components of the basement membrane, studies with urokinase-type plasminogen activator, alfathrombin and plasmin. Thromb Hemostasis 12: 335-336
17. Heuvel JPV, Clark GC, Kohn MC, Tritscher AM, Greenlee WF, Lucier GW and Bell DA (1994) Dioxin-responsive genes, examination of dose-response relationships using quantitative reverse transcriptase-polymerase chain reaction. Cancer Res 54: 62-68
18. Hollas W and Boyd D (1991) Urokinase-dependent proteolysis in cultured colon cancer is directed by its receptor. Semin Thromb Hemost 17: 225-230
19. Ishikawa N, Endo Y and Sasaki T (1996) Inverse correlation between mRNA expression of plasminogen activator inhibitor-2 and lymph node metastasis in human breast cancer. Jpn J Cancer Res 87: 480-487
20. Kirchheimer JC and Remold HG (1989) Functional characteristics of receptor-bound urokinase on human monocytes, catalytic efficiency and susceptibility to inactivation by plasminogen activation inhibitors. Blood 74: 1396-1402
21. Laug WE, Cao XR, Yu YB, Shimada H and Kruithof EKO (1993)Inhibition of invasion of HT1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2. Cancer Res 53: 6051-6657
22. Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V and Garbisa S (1981) Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 41: 4629-4636
23. Maurer F and Medcalf RL (1996) Plasminogen activator inhibitor type 2 gene induction by tumor necrosis factor and phorbol ester involves transcriptional and post-transcriptional events, identification of a functional nonameric AU-rich motif in the 3′-untranslated region. J Biol Chem 271: 26074-26080
24. Mueller BM, Yu YB and Laug WE (1995) Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice. Proc Natl Acad Sci USA 92: 205-209
25. Nagayama M, Sato A, Hayakawa H, Urano T, Takada Y and Takada A (1994) Plasminogen activators and their inhibitors in non-small cell lung cancer, low content of type 2 plasminogen activator inhibitor associated with tumor dissemination. Cancer 73: 1398-1405
26. Naitoh H, Eguchi Y, Ueyama H, Kodama M and Hattori T (1995)Localization of urokinase-type plasminogen activator inhibitor-1,2 and plasminogen in colon cancer. Jpn J Cancer Res 86: 48-56
27. Nielsen LS, Andreasen PA, Grondahl-Hansen J, Skriver L and Dano K (1986) Plasminogen activators catalyze conversion of inhibitor from fibrosarcoma cells to an inactive form with a lower apparent molecular mass. FEBS Lett 196: 269-273
28. Noguchi-Takino M, Endo Y, Yonemura Y and Sasaki T (1996) Relationship between expression of plasminogen activator system and metastatic ability in human cancers. Int J Oncol 8: 97-105
29. Olson D, Pöllänen J, Hoyer-Hansen G, Ronne E, Sakaguchi K and Wun TC (1992) Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. J Biol Chem 267: 9129-9133
30. Ossowski L (1988) In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase. J Cell Biol 107: 2437-2445
31. Pöllänen J, Vaheri A, Tapiovaara H, Riley E, Bertram K and Woodrew G (1990) Pro-urokinase activation on the surface of human rhabdomyosarcoma cells, localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor. Proc Natl Acad Sci USA 87: 2230-2234
32. Pöllänen J, Stephenes RW and Vaheri A (1991) Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res 57: 273-328
33. Pyke C, Kristensen P, Raltkiaer E, Grondahl-Hansen J and Brasi F (1991) Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasion foci in human colon adenocarcinomas. Am J Pathol 138: 1059-1067
34. Robbins KC, Summaria L, Hsieh B and Shah RJ (1967) The peptide chains of human plasmin, mechanism of activation system of human plasminogen to plasmin. J Biol Chem 242: 2333-2342
35. Salo T, Liotta LA, Keski-Oja J, Turpeenniem-Hujanen T and Tryggvason K (1982) Secretion of basement membrane collagen degrading enzyme and plasminogen activator by transformed cells - role in metastasis. Int J Cancer 30: 669-673
36. Testa JE and Quigley JP (1990) The role of urokinase-type plasminogen activator in aggressive tumor cell behavior. Cancer Metastasis Rev 9: 353-367
37. The Japan Lung Cancer Society (1995) General Rules for Clinical and Pathological Records of Lung Cancer, 4th edn. Kanehara: Tokyo
38. Veale D, Needham G and Harris AL (1990) Urokinase receptors in lung cancer and normal lung. Anticancer Res 10: 417-422